Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Regeneron Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
August 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports Second Quarter 2024 Financial and Operating Results
August 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
July 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
June 28, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
June 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
June 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
May 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
May 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports First Quarter 2024 Financial and Operating Results
May 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
April 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
April 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
April 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 12, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
March 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
March 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.